3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Hepatocellular
15
Esophageal Neoplasms
12
Colorectal Neoplasms
9
Stomach Neoplasms
6
Rectal Neoplasms
6
Esophageal Squamous Cell Carcinoma
6
Pancreatic Neoplasms
5
Neoplasms
4
Liver Neoplasms
4
Cholangiocarcinoma
4
Neoplasm Metastasis
3
Melanoma
3
Carcinoma, Renal Cell
3
Liver Diseases
2
Gastrointestinal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Adenocarcinoma
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Unresectable Hepatocellular Carcinoma
1
Unresectable Biliary Tract Cancer
1
Triple Negative Breast Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Interventions
pembrolizumab
12
Nivolumab
6
Cyclophosphamide
6
fludarabine
5
Ipilimumab
4
amatuximab
3
Cisplatin
3
tislelizumab
2
spartalizumab
2
fludarabine phosphate
2
budigalimab
2
belinostat
2
Plicamycin
2
Hyperthermic Intraperitoneal Chemotherapy
2
Fluorouracil
2
Cytoreduction Surgical Procedures
2
venetoclax
1
tocilizumab
1
talazoparib
1
sotorasib
1
rovalpituzumab tesirine
1
obinutuzumab
1
niraparib
1
naptumomab estafenatox
1
milademetan
1
irinotecan sucrosofate
1
epacadostat
1
enzalutamide
1
durvalumab
1
defactinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma
×
Immunotherapy
×
Gastrointestinal
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled